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Management of ampullary adenocarcinoma – not yet time for a paradigm
shift
As advanced endoscopic therapies become an increasingly integral tool in our armamentarium for managing
peri-ampullary lesions, we must remain vigilant in assessing outcomes to ensure that adequate oncologic
principles are observed. In this issue of HPB, Askew and Connor conducted a systematic review of contem-
porary investigation andmanagement of ampullary adenocarcinoma.Reports are increasingly emerging from
multiple centers describing definitive endoscopic management of T1 ampullary adenocarcinoma, and the
present review appropriately cautions the HPB community to tread cautiously in this approach. As outlined
in the present report, the high incidence of lymphnodemetastases associatedwithT1 lesions (8-43%), and the
limitation of current stagingmodalities to determine nodal status (EUS 60-81% sensitivity) risks undertreat-
ing a potentially curable cancerwith ampullectomy alone. In addition, thoughWoo et al.has suggested that the
incidence of nodal metastasis is very low (6%) with careful selection of patients with well-differentiated
tumors, negative resectionmargins, and no angiolymphatic invasion,pathologic assessment of these variables
on endoscopic ampullectomy specimens can be very difficult. As highlighted by Bellizzi et al. 2009, the
specimen is often fragmented with significant cautery artifact rendering an unevaluable margin up to a third
of the time, and on occasion portions of the sample are lost leading to a potential sampling error in evaluating
these specimen for foci of invasive disease.Thus,while our endoscopic colleagues provide a great resource and
step forward for management of truly benign peri-ampullary lesions, extension of this practice into manage-
ment of early stage adenocarcinoma should only be explored in the context of a prospective trial.
Rebecca Minter
Would you have your total pancreatectomy again?
As we ride the sine curve of enthusiasm for total pancreatectomy (TP), we seem to be on another upswing.
It is no longer as technically daunting as in the past; instead today it can be accomplished safely, even with
the laparoscope and robot. Some patients, such as those with chronic pancreatitis, can even have their own
pancreatic islets recovered and autotransplanted.Most patients however require more conventional remedies
for the endocrine and exocrine insufficiency guaranteed to follow TP, but these too have certainly improved
(insulin pumps, enzyme supplements). Barbier et al. now provide a detailed analysis of both short- and
long-term outcomes for 56 patients who underwent elective TP over 17 years at Hopital Beaujon in Paris.We
see acceptable morbidity, mortality and survival rates but more importantly, just how their results compare
with other contemporary published TP series. We see data clarifying that disease selection, and not just
patient selection, is critical for the best outcomes. Indeed, non-invasive diffuse IPMN was their most
frequent indication. We also learn of troubling TP complications such as gastric venous congestion and
anastomotic ulcers. Patients themselves were queried with validated methods on just how they felt long-
term,making this the fourth published study to evaluate long-termQoL after TP. The realities and challenges
were clear. Exocrine insufficiency negatively impacted at least 20% of patients on a daily basis. TP-induced
diabetes was difficult to control with frequent episodes of hypoglycemia and hospital readmissions. It
appears that for patients and surgeons alike, one truth still holds. Total pancreatectomy is not for everyone.
Mark Callery
Cardiopulmonary exercise (CPEX) testing is useful for patients being
considered for pancreaticoduodenectomy: but not for the reasons you
would think!
Significant morbidity, mortality and poor long-term survival following pancreaticoduodenectomy remain a
reality for those patients diagnosed with pancreatic adenocarcinoma. Selecting accurately those who will
actually gain benefit from pancreaticoduodenectomy remains a significant challenge. In this issue of HPB,
Chandrabalan et al. describe the outcomes of 100 patients who underwent pre-operative CPEX testing prior
to major pancreatic resection. Of the described cohort, 49% had what was considered to be a low anaerobic
threshold (<10 ml/kg/min) and were shown to be at increased risk of major intra-abdominal complications
such as significant pancreatic fistula and intra abdominal abscesses. Thus, not surprisingly they had a
prolonged hospital stay (median 6 days extra) and subsequently were less likely to receive adjuvant therapy.
The frequency of a low anaerobic threshold was much greater than that reported elsewhere. Is this just a
phenomenon associated with patients from Glasgow, selection bias – since not all patients underwent CEPX
testing, or is it the reality for patients presenting with pancreatic malignancy? It will be important to explore
these issues ifmore sensitivemarkers of quality are tobedeveloped rather than just purely crudemorbidity and
mortality rates. Is this low anaerobic threshold independent of other risk factors associatedwith increased risk
of pancreatic fistula? If so, it needs to be incorporated into fistula risk scores. Perhaps the most important
finding is the independent association with reduced use of adjuvant therapy in those with a low anaerobic
threshold. Surgery alone has little to offer patients with pancreatic adenocarcinoma. The ability to select out
accurately the 30% of patients who will die within the first 12 months following surgery would be a major
advance. Further studies looking at anaerobic threshold and long-term survival could be very useful indeed.
Saxon Connor
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